| Literature DB >> 29215273 |
Samantha J Mascuch, Paul D Boudreau, Tristan M Carland1, N Tessa Pierce, Joshua Olson, Mary E Hensler, Hyukjae Choi2, Joseph Campanale, Amro Hamdoun, Victor Nizet, William H Gerwick, Teresa Gaasterland, Lena Gerwick.
Abstract
The cyanobacterial marine natural product honaucin A inhibits mammalian innate inflammation in vitro and in vivo. To decipher its mechanism of action, RNA sequencing was used to evaluate differences in gene expression of cultured macrophages following honaucin A treatment. This analysis led to the hypothesis that honaucin A exerts its anti-inflammatory activity through activation of the cytoprotective nuclear erythroid 2-related factor 2 (Nrf2)-antioxidant response element/electrophile response element (ARE/EpRE) signaling pathway. Activation of this pathway by honaucin A in cultured human MCF7 cells was confirmed using an Nrf2 luciferase reporter assay. In vitro alkylation experiments with the natural product and N-acetyl-l-cysteine suggest that honaucin A activates this pathway through covalent interaction with the sulfhydryl residues of the cytosolic repressor protein Keap1. Honaucin A presents a potential therapeutic lead for diseases with an inflammatory component modulated by Nrf2-ARE.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29215273 PMCID: PMC6553616 DOI: 10.1021/acs.jnatprod.7b00734
Source DB: PubMed Journal: J Nat Prod ISSN: 0163-3864 Impact factor: 4.050